VISTIN PHARMA ASA (VISTN.OL) Stock Fundamental Analysis
Europe - OSL:VISTN - NO0010734122 - Common Stock
20.5 NOK
+0.2 (+0.99%)
Taking everything into account, VISTN scores 5 out of 10 in our fundamental rating. VISTN was compared to 54 industry peers in the Pharmaceuticals industry. While VISTN has a great health rating, its profitability is only average at the moment. VISTN has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
VISTN had positive earnings in the past year.
VISTN had a positive operating cash flow in the past year.
In multiple years VISTN reported negative net income over the last 5 years.
In multiple years VISTN reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of VISTN (18.05%) is better than 96.30% of its industry peers.
The Return On Equity of VISTN (25.86%) is better than 70.37% of its industry peers.
VISTN's Return On Invested Capital of 21.14% is amongst the best of the industry. VISTN outperforms 85.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.05% | ||
| ROE | 25.86% | ||
| ROIC | 21.14% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of VISTN (16.84%) is better than 70.37% of its industry peers.
VISTN's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 21.56%, VISTN perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
VISTN's Operating Margin has improved in the last couple of years.
VISTN has a Gross Margin (66.38%) which is in line with its industry peers.
VISTN's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.56% | ||
| PM (TTM) | 16.84% | ||
| GM | 66.38% |
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VISTN is creating value.
There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VISTN has an Altman-Z score of 6.87. This indicates that VISTN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.87, VISTN belongs to the best of the industry, outperforming 92.59% of the companies in the same industry.
The Debt to FCF ratio of VISTN is 0.56, which is an excellent value as it means it would take VISTN, only 0.56 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.56, VISTN belongs to the top of the industry, outperforming 92.59% of the companies in the same industry.
A Debt/Equity ratio of 0.14 indicates that VISTN is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.14, VISTN is doing good in the industry, outperforming 79.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.56 | ||
| Altman-Z | 6.87 |
ROIC/WACC2.48
WACC8.52%
2.3 Liquidity
VISTN has a Current Ratio of 1.73. This is a normal value and indicates that VISTN is financially healthy and should not expect problems in meeting its short term obligations.
VISTN has a Current ratio of 1.73. This is in the better half of the industry: VISTN outperforms 66.67% of its industry peers.
VISTN has a Quick Ratio of 1.73. This is a bad value and indicates that VISTN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.94, VISTN is in line with its industry, outperforming 44.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.41% over the past year.
The Earnings Per Share has been decreasing by -1.03% on average over the past years.
The Revenue has been growing slightly by 3.23% in the past year.
Measured over the past years, VISTN shows a quite strong growth in Revenue. The Revenue has been growing by 13.56% on average per year.
EPS 1Y (TTM)11.41%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%-3.59%
Revenue 1Y (TTM)3.23%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.92%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
VISTN is valuated reasonably with a Price/Earnings ratio of 11.92.
Based on the Price/Earnings ratio, VISTN is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of VISTN to the average of the S&P500 Index (26.06), we can say VISTN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.92 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VISTN is valued cheaply inside the industry as 83.33% of the companies are valued more expensively.
85.19% of the companies in the same industry are more expensive than VISTN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.02 | ||
| EV/EBITDA | 7.67 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.90%, VISTN is a good candidate for dividend investing.
VISTN's Dividend Yield is rather good when compared to the industry average which is at 2.89. VISTN pays more dividend than 94.44% of the companies in the same industry.
VISTN's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.9% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
101.97% of the earnings are spent on dividend by VISTN. This is not a sustainable payout ratio.
DP101.97%
EPS Next 2YN/A
EPS Next 3YN/A
OSL:VISTN (11/10/2025, 10:01:57 AM)
20.5
+0.2 (+0.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.3%
Inst Owner ChangeN/A
Ins Owners5.62%
Ins Owner ChangeN/A
Market Cap908.97M
Revenue(TTM)451.83M
Net Income(TTM)76.10M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.9% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP101.97%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.92 | ||
| Fwd PE | N/A | ||
| P/S | 2.01 | ||
| P/FCF | 12.02 | ||
| P/OCF | 9.69 | ||
| P/B | 3.09 | ||
| P/tB | 3.09 | ||
| EV/EBITDA | 7.67 |
EPS(TTM)1.72
EY8.39%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.71
FCFY8.32%
OCF(TTM)2.12
OCFY10.32%
SpS10.19
BVpS6.64
TBVpS6.64
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.05% | ||
| ROE | 25.86% | ||
| ROCE | 30.77% | ||
| ROIC | 21.14% | ||
| ROICexc | 21.27% | ||
| ROICexgc | 21.27% | ||
| OM | 21.56% | ||
| PM (TTM) | 16.84% | ||
| GM | 66.38% | ||
| FCFM | 16.74% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
F-Score7
Asset Turnover1.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.56 | ||
| Debt/EBITDA | 0.36 | ||
| Cap/Depr | 92.47% | ||
| Cap/Sales | 4.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.15% | ||
| Profit Quality | 99.4% | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | 6.87 |
F-Score7
WACC8.52%
ROIC/WACC2.48
Cap/Depr(3y)280.38%
Cap/Depr(5y)338.81%
Cap/Sales(3y)11.99%
Cap/Sales(5y)13.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.41%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%-3.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.23%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.61%
EBIT growth 3Y36.89%
EBIT growth 5Y38.44%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.44%
FCF growth 3YN/A
FCF growth 5Y158.58%
OCF growth 1Y16.97%
OCF growth 3Y99.03%
OCF growth 5Y41.62%
VISTIN PHARMA ASA / VISTN.OL FAQ
What is the fundamental rating for VISTN stock?
ChartMill assigns a fundamental rating of 5 / 10 to VISTN.OL.
What is the valuation status of VISTIN PHARMA ASA (VISTN.OL) stock?
ChartMill assigns a valuation rating of 4 / 10 to VISTIN PHARMA ASA (VISTN.OL). This can be considered as Fairly Valued.
Can you provide the profitability details for VISTIN PHARMA ASA?
VISTIN PHARMA ASA (VISTN.OL) has a profitability rating of 5 / 10.
Can you provide the financial health for VISTN stock?
The financial health rating of VISTIN PHARMA ASA (VISTN.OL) is 7 / 10.
How sustainable is the dividend of VISTIN PHARMA ASA (VISTN.OL) stock?
The dividend rating of VISTIN PHARMA ASA (VISTN.OL) is 5 / 10 and the dividend payout ratio is 101.97%.